Abstract
HIV protease (HIV PR) has been identified as a key target in the treatment of HIV infection, and antiviral drugs that block its proteolytic activity have been developed. However, there are numerous ways in which a drug can lose effectiveness during long-term therapy. In particular several protease-mediated mechanisms result in reduced antiviral sensitivity of the various anti HIV protease inhibitors. As with inhibitors of reverse transcriptase, protease inhibitors have shown a sensitivity to variations in the protease that weaken drug affinities, both in cell culture and in vivo [1,2]. These include: 1) mutations of active site residues that are direct substrate specificity determinants; 2) mutations of non-active site residues that indirectly interfere with inhibitor binding through long range structural changes; 3) mutations that increase enzyme catalysis; 4) mutations that increase enzyme stability and half-life; and 5) mutations that provide new substrate specificities with corresponding mutations in the gag—pol polyprotein precursor substrate. Since the binding modes of both the natural substrates for HIV protease and the substrate analog class of inhibitors are similar, amino acid substitutions that occur in the substrate binding pocket are among the more common resistance mutations that arise in response to HIV protease inhibitors. However, the structural basis for the loss of sensitivity of a viral protease to a drug is not always obvious or predictable. This inability to anticipate the variety of mechanisms of viral resistance to new protease inhibitors complicates the task of designing more effective drugs. In this work, we consider the possibility of creating a new class of inhibitors that can pose a greater challenge to the development of protease-mediated viral resistance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M and et al., In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374(6522): 569–71, 1995.
Mellors J, Schinazi R and Larder B, Mutations in HIV-1 RT and protease. In: Human Retroviruses and AIDS (Eds. Myers G, Wain-Hobson S, Henderson LE, Korber B, Jeang K-T and Pavlakis GN). Theoretical Biology & Biophysics, Los Alamos, New Mexico, updated 1995.
Winslow DL, Stack S, King R, Scarnati H, Bincsik A and Otto MJ, Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res Hum Retroviruses 11(1): 107–13, 1995.
Babé LM, Rosé J and Craik CS, Synthetic “interface” peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Science 1(10): 1244–53, 1992.
Schramm HJ, Billich A, Jaeger E, Rucknagel KP, Arnold G and Schramm W, The inhibition of HIV-1 protease by interface peptides. Biochem Biophys Res Commun 194(2): 595–600, 1993.
Zhang ZY, Poorman RA, Maggiora LL, Heinrikson RL and Kezdy FJ, Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J Biol Chem 266(24): 15591–4, 1991.
Herskowitz I, Functional inactivation of genes by dominant negative mutations. Nature 329(6136): 219–22, 1987.
Babé LM, Rosé J and Craik CS, Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc Natl Acad Sci U S A 92(22): 10069–73, 1995.
Page KA, Landau NR and Littman DR, Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 64(11): 5270–6, 1990.
McPhee F, Good AC, Kuntz ID and Craik CS, Engineering HIV-1 protease heterodimers as macromolecular inhibitors of viral maturation. Proc. Natl. Acad. Sci. 93: 11477–81, 1996.
Tripos Associates Inc., SYBYL Molecular Modeling Package. Tripos Associates, St. Louis, Version 6.0, 1994.
Craik CS, Babé LM, Dauber D, McPhee F, Rosé J and Ünal A, Engineering catalytically defective forms of HIV protease to modulate its activity. In: Structure and Function of Aspartic Proteinases: Retroviral and Cellular Enzymes (Ed. James MNG). Plenum Publishing Corporation, New York, 1997.
Junker U, Escaich S, Plavec I, Baker J, McPhee F, Rosé JR, Craik CS and Böhnlein E, Intracellular expression of HIV-1 protease variants inhibits replication of wild-type and protease inhibitor resistant HIV-1 strains in human T cell lines. J. Virology 70: 7765–72, 1996.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Dauber, D.S., McPhee, F., Ünal, A., Craik, C.S. (1998). Optimization of a Macromolecular Inhibitor of HIV-1 Protease. In: James, M.N.G. (eds) Aspartic Proteinases. Advances in Experimental Medicine and Biology, vol 436. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5373-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5373-1_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7452-7
Online ISBN: 978-1-4615-5373-1
eBook Packages: Springer Book Archive